Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia
Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
Past Highlights
Results:
1 -10 of 551
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Title
Phase
Protocol IDs
Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
Phase IV
CZOL446EDE28
NCT00334139
Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
Phase IV
CZOL446GDE22
NCT00391690
Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases
Phase IV
CZOL446EAU22
NCT00434447
Prostate Cancer Study In Men Who Have Failed First-Line Androgen Deprivation Therapy
Phase IV
AVO108943
NCT00470834
Early Detection of Prostate Cancer by FACS
Phase IV
HP 7-251 S
NCT00524823
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Proscar in Men With Initial Negative Prostate Biopsies
Phase IV
2007_029
MK0906-143, NCT00547079
Radical Prostatectomy and Perioperative Fluid Therapy
Phase IV
RCT_PROST_ORTO
NCT00771966
Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
Phase IV
047838
NCT00805701
Enbrel Versus Placebo With Radiation Therapy to Combat Fatigue and Cachexia
Phase III, Phase II
001-0015-211
NCT00127387
Androgen Suppression Alone or Combined With Zoledronate, Docetaxel, Prednisolone, and/or Celecoxib in Treating Patients With Locally Advanced or Metastatic Prostate Cancer
Phase III, Phase II
MRC-STAMPEDE
EU-205102, MRC-PR08, ISRCTN78818544, EUDRACT-2004-000193-31, NCT00268476
1
2
3
4
Next >
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute